Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “BEAM-302 is a lipid nanoparticle (LNP)-based therapy for the treatment of patients with AATD”In the company’s words, NCT06389877 on ClinicalTrials.gov
- Tested for
- Alpha 1-Antitrypsin Deficiency
- Main trialPhase 1/2
- “This is a Phase 1/2, multicenter, open-label study conducted in 3 parts (Part A, Part B, and Part C) to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease. Parts A and B are designed to evaluate safety and tolerability and identify the optimal biological dose (OBD) in patients with AATD-associated lung disease (Part A) and/or liver disease (Part B), with optional expansion cohorts to further evaluate a potential OBD. Part C is designed to demonstrate the efficacy and safety of BEAM-302 at the OBD in…”In the company’s words, NCT06389877 on ClinicalTrials.gov
Other drugs for Alpha 1-Antitrypsin Deficiency
- Alpha-1 MPGrifols Therapeutics LLC · Phase 3
- FazirsiranTakeda · Phase 3
- WVE-006Wave Life Sciences · Phase 1/2
- SAR447537Sanofi · Phase 2
- PM647aPrime Medicine, Inc. · Phase 1/2
- TSRA-196Tessera Therapeutics, Inc. · Phase 1/2
Coming up1
- May 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | May 2028 | A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026